Biomarker strategies using blood microRNA to predict pharmacokinetics
| Project/Area Number |
23590186
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
HIROTA TAKESHI 九州大学, 薬学研究科(研究院), 助教 (80423573)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Keywords | オーダーメード医療 / 薬物トランスポーター / microRNA |
|---|
| Research Abstract |
MicroRNA (miRNA) is a non-coding small RNA that regulates gene expression at the translational level by mainly interacting with 3'-untranslated region of target mRNA. It was reported that miR-328 expression influences on breast cancer resistance protein (BCRP) expression in cancer cells. We showed that the methylation patterns of several CpG dinucleotides proximal to identified two C/EBP binding sites in the pre-miR-328 5'-flanking regions were negatively correlated with miR-328 expression and positively associated with BCRP expression in the human placental samples. Recent studies suggested that circulating microRNAs as stable blood-based markers for cancer detection. We analyzed the association between circulating miR-328 expression and the pharmacokinetics of BCRP substrate drug. Circulating miR-328 expression was not significantly associated with the pharmacokinetics.
|
Report
(4 results)
Research Products
(9 results)
